SH PHARMA(02607),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

02607 SH PHARMA

Closed 03-19 16:09:10

12.080

+0.000

0.00%

High12.140	Low12.040	Vol2.86M
Open12.080	D1 Closing12.080	Amplitude0.83%
Mkt Cap44.79B	Tradable Cap11.10B	Total Shares3.71B
T/O34.57M	T/O Rate0.31%	Tradable Shares919.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"02607","market":"HK","secType":"STK","nameCN":"SH PHARMA","latestPrice":12.08,"timestamp":1742371750032,"preClose":12.08,"halted":0,"volume":2862901,"delay":0,"floatShares":919000000,"shares":3708000000,"eps":1.0938092599574198,"marketStatus":"Closed","change":0,"latestTime":"03-19 16:09:10","open":12.08,"high":12.14,"low":12.04,"amount":34566834,"amplitude":0.008278,"askPrice":12.08,"askSize":97500,"bidPrice":12.06,"bidSize":110000,"shortable":3,"etf":0,"ttmEps":1.1607117642154503,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1742434200000},"marketStatusCode":5,"adr":0,"listingDate":1305820800000,"exchange":"SEHK","adjPreClose":12.08,"dividendRate":0.043874,"openAndCloseTimeList":[[1742347800000,1742356800000],[1742360400000,1742371200000]],"volumeRatio":0.53324,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"601607","market":"SH","secType":"STK","nameCN":"Shanghai Pharmaceuticals Holding Co.,Ltd.","latestPrice":19.25,"timestamp":1742367600000,"preClose":19.23,"halted":0,"volume":6584900,"delay":0,"premium":"-41.59"}},"requestUrl":"/m/hq/s/02607/wiki","defaultTab":"wiki","newsList":[{"id":"2516061278","title":"Hutchmed Agrees to Dispose 35% of Subsidiary to GP Health Service Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2516061278","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516061278?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 14:05","pubTimestamp":1741068301,"startTime":"0","endTime":"0","summary":"Hutchmed (China) (HKG:0013) agreed to dispose of its 35% equity in Shanghai Hutchison Pharmaceuticals or SHPL to two entities under GP Health Service Capital for 3.48 billion yuan, according to a Hong","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1191","GP","BK0097","601607","00013","BK0188","BK1587","BK0175","BK4149","BK1588","BK0183","BK0187","BK0012","02607","BK0028","BK0099","BK0209","BK0196","BK1197","BK0184","BK0020"],"gpt_icon":0},{"id":"2507685099","title":"Shanghai Pharmaceuticals to Invest 1 Billion Yuan in Biomedical M&A Fund","url":"https://stock-news.laohu8.com/highlight/detail?id=2507685099","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507685099?lang=en_us&edition=full_marsco","pubTime":"2025-01-29 18:01","pubTimestamp":1738144877,"startTime":"0","endTime":"0","summary":"Shanghai Pharmaceuticals (HKG:2607) is proposing to take part in the establishment of the Biomedical M&A Fund as a limited partner alongside various other parties and contribute 1 billion yuan to the ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02607","BK1197"],"gpt_icon":0},{"id":"2500458659","title":"Shanghai Pharmaceuticals Holding and Yunnan Baiyao Renew Sales Agreement for 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2500458659","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500458659?lang=en_us&edition=full_marsco","pubTime":"2025-01-02 18:02","pubTimestamp":1735812155,"startTime":"0","endTime":"0","summary":"Shanghai Pharmaceuticals Holding  said its sales and procurement framework agreement between Shanghai Pharmaceuticals Holdings and Yunnan Baiyao expired on Dec. 31, but both companies are committed to continuing their transactions.On the same day, the board approved and executed the agreement, effective from Jan. 1, 2025, to Dec. 31, 2025, for mutual sales and procurement of various medical and health products, according to its filing on Wednesday.Yunnan Baiyao, holding a 17.95% stake in the company, is a substantial shareholder and thus a connected person as per the Listing Rules.Consequently, the transactions under this new agreement are classified as continuing connected transactions, requiring reporting and annual review but exempt from circular and independent shareholders' approval due to the applicable percentage ratios.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02607"],"gpt_icon":0},{"id":"2500991961","title":"Hutchmed Projects Gain of $477 Million From Hutchison Pharmaceutical Stake Disposal","url":"https://stock-news.laohu8.com/highlight/detail?id=2500991961","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500991961?lang=en_us&edition=full_marsco","pubTime":"2025-01-02 10:08","pubTimestamp":1735783723,"startTime":"0","endTime":"0","summary":"Hutchmed   expects to book a pre-tax gain of approximately $477 million after its wholly-owned subsidiary sold shares in Shanghai Hutchison Pharmaceuticals .The disposal involved selling a 35% stake to GP Health Service Capital for approximately $473 million and a 10% stake to Shanghai Pharma  for around $135 million.Before this transaction, SHPL, a joint venture operating its own-brand prescription drug business, was equally owned by Hutchmed's subsidiary and Shanghai TCM.With the completion of this sale, Hutchmed will maintain a 5% indirect interest in SHPL.Disposal proceeds will be used to bolster Hutchmed's core business operations and advance its antibody drug conjugate platform, according to a filing on Wednesday.Hutchmed's shares gained over 3% in early trading.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0183","BK0196","BK1587","02607","BK0188","00013","BK0184","BK0097","BK1588","BK0099","SHP.AU","BK0187","BK7095","BK0028","601607","BK0012","BK1191","SES.SI","BK1197","BK0175","BK0020","BK0209"],"gpt_icon":1},{"id":"2488136871","title":"Shanghai Pharma Gets Nod to Produce Apremilast Tablets","url":"https://stock-news.laohu8.com/highlight/detail?id=2488136871","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488136871?lang=en_us&edition=full_marsco","pubTime":"2024-12-04 13:44","pubTimestamp":1733291085,"startTime":"0","endTime":"0","summary":"Shanghai Pharmaceuticals'  unit, Changzhou Pharmaceutical Factory, received a drug registration certificate from the Chinese drug administration for its apremilast tablets, according to a Shanghai Stock Exchange filing on Wednesday.The pharmaceutical company spent 12.4 million yuan into the research and development of the drug, which is used to treat adult patients with moderate to severe plaque psoriasis.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0188","BK0028","BK0183","BK0020","02607","601607","BK0184","BK0187","BK0012","BK0099","BK0196","BK0175","BK1197","BK0209","BK0097"],"gpt_icon":0},{"id":"2488646701","title":"Shanghai Pharmaceuticals' Trial on Drug for Stroke Patients Shows Positive Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2488646701","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488646701?lang=en_us&edition=full_marsco","pubTime":"2024-12-02 13:44","pubTimestamp":1733118280,"startTime":"0","endTime":"0","summary":"Shanghai Pharmaceuticals  completed the analysis of the results of the Phase II clinical trial of LT3001, a drug used for the treatment of acute stroke and acute ischemic stroke, according to a Shanghai Stock Exchange filing on Saturday.The trial found that the drug was generally safe and well tolerated and it showed preliminary efficacy among subjects within 90 days of treatment.The rights of the drug were bought from Shuntian Pharmaceutical Biotech in 2019 and it was approved for clinical trials in 2020, the Chinese pharmaceutical company said.The company's shares fell 2% in recent trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0188","BK0175","BK0097","601607","BK0184","BK0196","BK0099","BK1197","BK0012","BK0028","BK0183","BK0187","BK0209","BK0020","02607"],"gpt_icon":0},{"id":"2481114515","title":"Shanghai Pharmaceuticals' Pentoxifylline Passes Generic Drug Evaluation in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2481114515","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481114515?lang=en_us&edition=full_marsco","pubTime":"2024-11-05 11:36","pubTimestamp":1730777798,"startTime":"0","endTime":"0","summary":"Shanghai Pharmaceuticals (HKG:2607, SHA:601607) said its generic version of pentoxifylline passed the National Medical Products Administration's consistency evaluation for generic drugs.Changzhou Phar","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02607","BK0020","BK0209","BK0187","BK0097","601607","BK0012","BK0028","BK0184","BK0175","BK0188","BK0183","BK0196","BK0099","BK1197"],"gpt_icon":0},{"id":"2479421228","title":"Shanghai Pharmaceuticals Report 6% Drop in Q3 Profit; Shares Slide 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2479421228","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479421228?lang=en_us&edition=full_marsco","pubTime":"2024-10-30 12:25","pubTimestamp":1730262329,"startTime":"0","endTime":"0","summary":"Shanghai Pharmaceuticals Holding  reported a net profit attributable to shareholders of 1.11 billion yuan for the quarter ended Sept. 30, a decrease of 6.29% compared with the prior-year period, according to a quarterly report filed on Tuesday with the Hong Kong Stock Exchange.Earnings per share for the company were 0.30 yuan, down 0.06% year on year.The company's operating revenue grew 8.16% on-year to 70.22 billion yuan.The pharma company's shares were down over 3% in the recent trading.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["601607","BK0188","BK0196","BK0099","02607","BK0187","BK0028","BK0184","BK0097","BK0209","BK1197","BK0183","BK0012","BK0020","BK0175"],"gpt_icon":0},{"id":"2473142992","title":"Shanghai Pharmaceuticals' Unit Gets Nod to Market Alfacalcidol","url":"https://stock-news.laohu8.com/highlight/detail?id=2473142992","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2473142992?lang=en_us&edition=full_marsco","pubTime":"2024-10-07 13:57","pubTimestamp":1728280672,"startTime":"0","endTime":"0","summary":"Shanghai Pharmaceuticals Holding's  subsidiary, Shanghai Xinyi Wanxiang Pharmaceutical, received approval from China's National Medical Products Administration to market its raw drug ingredient, Alfacalcidol, according to an Oct. 1 disclosure on the Shanghai Stock Exchange.The Chinese pharmaceutical company invested 4.4 million yuan into the research and development of the drug, which is mainly used to treat calcium metabolism disorders.Price : $14.58, Change: $+0.48, Percent Change: +3.40%","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0209","BK1197","BK0183","BK0184","BK4023","BK4585","BK0012","BK4526","BK0028","BK0187","BK0175","601607","BK0099","02607","BK4588","BK0188","BK0196","BK0097","BK0020"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.shaphar.com.cn","stockEarnings":[{"period":"1week","weight":0.0151},{"period":"1month","weight":-0.0082},{"period":"3month","weight":-0.0807},{"period":"6month","weight":0.1638},{"period":"1year","weight":0.0239},{"period":"ytd","weight":-0.0428}],"compareEarnings":[{"period":"1week","weight":0.0403},{"period":"1month","weight":0.0937},{"period":"3month","weight":0.2455},{"period":"6month","weight":0.3735},{"period":"1year","weight":0.4782},{"period":"ytd","weight":0.2333}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Shanghai Pharmaceuticals Holding Co Ltd is a China-based company principally engaged in pharmaceutical industry, distribution and retail business. The Company's products include innovative drugs, chemical drugs, traditional Chinese medicines and rare disease drugs. The Company's products are mainly used in the cardiovascular system, digestive tract and metabolism, systemic anti-infection, central nervous system, anti-tumor and immunomodulators, musculoskeletal system and respiratory system. In addition, the Company also provides medical logistics and warehousing services. The Company distributes its products both in the domestic market and to overseas markets.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.00299},{"month":2,"riseRate":0.571429,"avgChangeRate":0.01754},{"month":3,"riseRate":0.642857,"avgChangeRate":0.01617},{"month":4,"riseRate":0.538462,"avgChangeRate":0.003331},{"month":5,"riseRate":0.538462,"avgChangeRate":-0.00636},{"month":6,"riseRate":0.5,"avgChangeRate":-0.012586},{"month":7,"riseRate":0.285714,"avgChangeRate":-0.020804},{"month":8,"riseRate":0.428571,"avgChangeRate":0.005824},{"month":9,"riseRate":0.357143,"avgChangeRate":0.015401},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.020412},{"month":11,"riseRate":0.428571,"avgChangeRate":0.031213},{"month":12,"riseRate":0.571429,"avgChangeRate":-0.011642}],"exchange":"SEHK","name":"SH PHARMA","nameEN":"SH PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.31.7","shortVersion":"4.31.7","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"SH PHARMA(02607),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest SH PHARMA(02607) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"SH PHARMA,02607,SH PHARMA股票,SH PHARMA股票老虎,SH PHARMA股票老虎国际,SH PHARMA行情,SH PHARMA股票行情,SH PHARMA股价,SH PHARMA股市,SH PHARMA股票价格,SH PHARMA股票交易,SH PHARMA股票购买,SH PHARMA股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"SH PHARMA(02607),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest SH PHARMA(02607) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}